Comparison of two preventive treatments for patients with recurrent miscarriages carrying a C677T methylenetetrahydrofolate reductase mutation: 5-year experience

Merviel, Philippe; Cabry, Rosalie; Lourdel, E.; Lanta, S.; Amant, Carole; Copin, Henri; Benkhalifa, Moncef

doi:10.1177/0300060516675111

Cited by 13 publications

(20 citation statements)

References 46 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four studies were included in the NOS quality assessment, all of which were cohort studies [42][43][44][45]. A summary of the assessment is presented in the Electronic Supplementary Material (Table S4).…”

Section: Resultsmentioning

confidence: 99%

“…All studies scored the maximum score of 4 stars in the selection category, indicating that the data used was representative of the targeted community. For the comparability category, one study scored only one star because the authors did not describe any additional baseline characteristics that were well matched between cohorts [42] and the other three studies scored the maximum score of 2 stars [43][44][45]. Finally, in the outcome category, all studies scored the maximum of 3 stars.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis

Jacobson

Rambiritch

Paek³

et al. 2019

Adv Ther

View full text Add to dashboard Cite

Introduction: International guidelines support the use of low molecular weight heparins for the treatment of thromboembolism and thromboprophylaxis during pregnancy. However, evidence of the benefit and harm associated with specific low molecular weight heparins such as enoxaparin is dated. No current systematic review and meta-analysis describing the safety and efficacy of enoxaparin for thromboembolism and thromboprophylaxis during pregnancy exists. Methods: PubMed, Embase, and Cochrane databases were searched on August 17, 2018 for clinical trials or observational studies in pregnant women receiving enoxaparin; patients with a prosthetic heart valve were excluded. Risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random effects model, and heterogeneity was measured using the I 2 statistic.Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.9933413.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis

Jacobson

Rambiritch

Paek³

et al. 2019

Adv Ther

View full text Add to dashboard Cite

show abstract

“…Folate (5 mg/day) and aspirin with or without enoxaparin (0.4 mg/day) were administered. The authors observed a much higher delivery rate in the group receiving anti-coagulant (79.7%) in comparison to those receiving only folate and aspirin (46.3%) [84]. Though the exact reason for better efficacy of the treatment regimen incorporating the anti-coagulant could be complex, this may be related to blood clots in fine vasculature as a result of MTHFR mutations and hyper-homocysteinemia [85].…”

Section: Discussionmentioning

confidence: 98%

“…Some other studies have tried different combinations of medicines for RPL management in consultation with MTHFR genotyping. For example, Merviel et al (2017) recruited MTHFR 677C>T mutant females to study their response to treatment. Folate (5 mg/day) and aspirin with or without enoxaparin (0.4 mg/day) were administered.…”

Section: Discussionmentioning

confidence: 99%

MTHFR 1298A>C Substitution is a Strong Candidate for Analysis in Recurrent Pregnancy Loss: Evidence from 14,289 Subjects

et al. 2021

View full text Add to dashboard Cite

We undertook meta-analyses on MTHFR 1298A>C substitution for critically evaluating its association with recurrent pregnancy loss (RPL). MTHFR genotype data for 5888 cases and 8401 controls from 39 studies were pooled to perform this meta-analyses. Genotype data were screened, scrutinized, pooled, analysed and subjected to sensitivity analysis to carefully evaluate the association between MTHFR 1298A>C and recurrent pregnancy loss. Genetic associations were sought using dominant, recessive and co-dominant models of genetic testing with odds ratio and 95% Confidence interval (CI) as the effect measures. Further analyses were undertaken by classifying the studies into Caucasian and East Asian sub-groups. Genetic heterogeneity was tested before pooling the data across studies. For assessing publication bias, Egger's intercept test was undertaken. We found a significant association of 1298A>C substitution with increased risk of RPL in the dominant (P=0.000; OR = 1.58; 95% CI =1.25-1.99) as well as recessive (P=0.000; OR = 1.66; 95% CI =1.25-2.20) models. In sub-group analysis, we observed a significant association of the polymorphism with RPL in the Caucasian populations using dominant (P=0.000; OR = 1.98; 95% CI =1.42-2.76) and recessive (P=0.000; OR = 2.20; 95% CI =1.49-3.24) models. However, this substitution showed no association with RPL in the East Asian populations (P=0.149; OR = 1.187; 95% CI =0.94-1.50). MTHFR 1298A>C substitution shows association with the risk of recurrent pregnancy loss. The association is in a population-specific manner with the substitution being a strong risk factor only in the Caucasian populations.

show abstract

“…Research studies notify that HHcy can be generated by the specific mutation in MTHFR. This inherited deficiency lead to a 3.3-fold increase in the risk of miscarriage in a sample group of 185 Caucasian women [32,33]. Literature also specifies that associations between MTHFR C667T mutations to factor V Leiden and prothrombin gene mutations were identified in patients having recurrent miscarriages [34].…”

Section: Miscarriagementioning

confidence: 98%

Is Homocysteine a Marker or a Risk Factor: A Question Still Waits for an Answer

Filip¹,

Albu²,

Hurjui³

et al. 2018

Non-Proteinogenic Amino Acids

View full text Add to dashboard Cite

Homocysteine, a non-proteinogenic sulfur-containing amino acid, was discovered in 1932, and 30 years passed until, in 1969, for the first time, its involvement in pathology was reported. It was only in the last two decades that homocysteine has become a subject of scientific interest and has begun to be intensively studied. A large number of scientists consider homocysteine as an independent risk factor particularly for cardiovascular disease, while others indicate homocysteine as a marker of this disease. Both sides bring scientific arguments for their opinions, yet the dilemma of homocysteine characterization still persists. Although the reported studies do not lead to a unique answer, it is generally accepted that homocysteine is associated with vascular dysfunction. Numerous scientific data show that the link between homocysteine and inflammation is achieved via the reactive oxygen species (ROS) pathway. The latest data indicate hydrogen peroxide as a possible messenger in cellular signaling in physiological or pathological processes and present the consequences of disturbing the oxidation-reducing balance. In this chapter, we present the latest scientific evidences gathered from the literature for both hypotheses regarding homocysteine involvement in pathology, and we propose a possible mechanism of action for homocysteine, based on our preliminary (yet unpublished) work.

show abstract

Comparison of two preventive treatments for patients with recurrent miscarriages carrying a C677T methylenetetrahydrofolate reductase mutation: 5-year experience

Cited by 13 publications

References 46 publications

Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis

Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis

MTHFR 1298A>C Substitution is a Strong Candidate for Analysis in Recurrent Pregnancy Loss: Evidence from 14,289 Subjects

Is Homocysteine a Marker or a Risk Factor: A Question Still Waits for an Answer

Contact Info

Product

Resources

About